Results 91 to 100 of about 5,297,540 (313)

Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients

BMC Gastroenterology, 2023
Background Neoadjuvant therapy favors the prognosis of various cancers, including esophagogastric junction cancer (EGC). However, the impacts of neoadjuvant therapy on the number of dissected lymph nodes (LNs) have not yet been evaluated in EGC.
Qi Wang, Jin-tong Ge, Hua Wu, Sheng Zhong, Qing-quan Wu   +4 more
doaj   +1 more source

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer

Frontiers in Oncology, 2022
BackgroundNeoadjuvant therapy is a standard treatment for patients with large, nonmetastatic breast cancer and may allow breast-conserving surgery after tumor downsizing while decreasing the risk of subsequent relapse.
Jinmei Zhou, Jiangling Wu, Jiangling Wu, Xiaopeng Hao, Ping Li, Huiqiang Zhang, Xuexue Wu, Jiaxin Chen, Jiawei Liu, Jinyi Xiao, Shaohua Zhang, Zefei Jiang, Yanlian Yang, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Tao Wang   +18 more
doaj   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer [PDF]

, 2015
Introduction Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common.
A Mackay, AK Dunbier, AK Dunbier, Alan Mackay, Alexey Larionov, Anita K Dunbier, Aradhana Rani, Ash Nerurkar, B Weigelt, BP Coe, C Curtis, C Kent, D Generali, DG Albertson, DS Tan, Elena López-Knowles, F Kreisel, Helen Anderson, HW Cheung, IE Smith, IE Smith, J Hicks, J Michael Dixon, Jorge S Reis-Filho, JS Foster, K Lundgren, L Osterberg, LA Martin, LA Martin, LA Martin, Lesley-Ann Martin, LG Leon, Lorna Renshaw, M Dowsett, M Mello-Grand, M Scaltriti, Mitch Dowsett, MJ Ellis, MT Weigel, N Turner, P Darbre, P Lal, Paul M Wilkerson, Peter Osin, PM Wilkerson, PM Wilkerson, PT Simpson, R Beroukhim, R Duprez, R Katz-Brull, R Natrajan, R Natrajan, R Natrajan, Ricardo Ribas, T Miyake, T Troiani, TK Lam, William R Miller, WR Miller, WR Miller, WR Miller, WR Miller, X Huo, Y Zhao, Z Ghazoui, Zara Ghazoui   +65 more
core   +3 more sources

Placement of a self-expandable metallic stent as a bridge to surgery for large bowel obstruction induced by effective neoadjuvant therapy: report of three cases

Surgical Case Reports, 2018
Background Self-expandable metallic stent placement is a widely performed palliative procedure or bridge to surgery for obstructive colorectal cancer. However, the feasibility of this procedure for large bowel obstruction induced by effective neoadjuvant
Fumihiko Ando, Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Nobuyuki Sakurazawa, Youichi Kawano, Hiroshi Yoshida   +6 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Evaluation of the Systemic and Regional Antibiotic Therapy Effectiveness as Part of Complex Therapy in Patients with Locally Spread Breast Cancer [PDF]

, 2019
In recent years, breast cancer is the most common oncologic pathology and the most common cause of disability among women in developed countries.The aim of the study.
Bondar, O. (Oleksandr)
core  

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. [PDF]

, 2016
In this study, the prognostic significance of tumor metrics derived from diffusion tensor imaging (DTI) was evaluated in patients with locally advanced breast cancer undergoing neoadjuvant therapy.
Harnish, Roy, Hylton, Nola M, Li, Wen, Newitt, David C, Proctor, Evelyn, Shin, Hee Jung, Wilmes, Lisa J   +6 more
core   +1 more source

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy

Chronic Diseases and Translational Medicine, 2016
Neoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete response (pCR) can be achieved in 12%–38% of patients. Patients with pCR have the most favorable long-term outcomes.
Jian Cui, Hui Fang, Lin Zhang, Yun-Long Wu, Hai-Zeng Zhang   +4 more
doaj   +1 more source